Clairity, Inc. has achieved a groundbreaking milestone in breast cancer prevention, receiving U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, the first AI platform authorized to predict five-year breast cancer risk from routine screening mammograms. The Boston and Chicago-based digital health company plans to launch the platform among leading health systems throughout 2025.
Revolutionary Approach to Risk Assessment
CLAIRITY BREAST represents a paradigm shift in breast cancer risk prediction by analyzing subtle imaging features on screening mammograms that correlate with future breast cancer risk. Unlike traditional risk assessment models that rely heavily on age and family history, this AI-driven platform can identify patterns invisible to the human eye, enabling risk prediction based solely on a screening mammogram.
The platform delivers validated five-year risk scores to healthcare providers through existing clinical infrastructures, supporting more personalized follow-up care for patients.
Addressing Critical Healthcare Gaps
The authorization comes at a crucial time when breast cancer remains a global health challenge, with more than 2.3 million new cases diagnosed worldwide annually, including over 370,000 cases in women in the United States. Current risk assessment approaches face significant limitations that CLAIRITY BREAST aims to address.
"85% of women diagnosed with breast cancer have no family history, and nearly half have no identifiable risk factors," according to the company's data. Additionally, traditional risk models built on data from predominantly European Caucasian women have not generalized well to women of diverse racial and ethnic backgrounds.
Clinical Expert Perspectives
Dr. Connie Lehman, Founder of Clairity and breast imaging specialist at Mass General Brigham, emphasized the transformative potential of the technology. "For more than 60 years, mammograms have saved lives by detecting early-stage cancers. Now, advancements in AI and computer vision can uncover hidden clues in the mammograms – invisible to the human eye – to help predict future risk," she said. "By delivering validated, equitable risk assessments, we can help expand access to life-saving early detection and prevention for women everywhere."
Dr. Robert A. Smith, Senior Vice President of Early Cancer Detection Science at the American Cancer Society, highlighted the broader implications for personalized screening. "Personalized, risk-based screening is critical to improving breast cancer outcomes, and AI tools offer us the best opportunity to fulfill that potential," he stated. "By integrating AI models that assess individual risk, we can better identify women at higher risk, and those who may benefit from supplemental screening methods, such as MRI, improving early detection and more effective prevention strategies."
Advancing Precision Medicine
The FDA's De Novo authorization pathway, typically reserved for novel medical devices with no predicate, underscores the innovative nature of CLAIRITY BREAST. This first-in-class platform represents a significant advancement toward precision medicine in breast cancer care, potentially enabling more targeted screening strategies and interventions based on individual risk profiles.
The technology's ability to provide risk assessment from routine screening mammograms alone could streamline clinical workflows while enhancing the precision of breast cancer prevention strategies. As Clairity prepares for its 2025 launch across leading health systems, the platform promises to usher in a new era of AI-driven, equitable healthcare solutions in breast cancer management.
